AGE - AgeX Therapeutics Inc Stock Price, Fair Value and News

$4.900.00 (0.00%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

AGE Price Action

Last 7 days

10.8%

Last 30 days

-37.3%

Last 90 days

-32.3%

Trailing 12 Months

-77.0%

AGE RSI Chart

AGE Valuation

Market Cap

43.6M

Price/Earnings (Trailing)

3.16

Price/Sales (Trailing)

14.86

EV/EBITDA

-3.18

Price/Free Cashflow

-4.68

AGE Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

AGE Fundamentals

AGE Revenue

Revenue (TTM)

3.2M

Rev. Growth (Yr)

-99.32%

Rev. Growth (Qtr)

-72.55%

AGE Earnings

Earnings (TTM)

13.8M

Earnings Growth (Yr)

126.11%

Earnings Growth (Qtr)

-72.91%

AGE Profitability

Operating Margin

98.73%

EBT Margin

-317.84%

Return on Equity

-99.75%

Return on Assets

185.53%

Free Cashflow Yield

-21.38%

AGE Investor Care

Shares Dilution (1Y)

736.79%

Diluted EPS (TTM)

4.42

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	616.5K	611.5K	1.5M	3.2M
2022	255.9K	367.8K	479.6K	591.5K
2021	306.8K	252.5K	198.3K	144.0K
2020	1.9M	1.5M	940.5K	361.0K
2019	1.5M	1.5M	1.5M	1.7M
2018	1.4M	1.4M	1.4M	1.4M
2017	0	0	0	1.4M

Get all data in R, Python etc through our Historical Stock Data APIs

About AgeX Therapeutics Inc

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.

CEO	Dr. Joanne M. Hackett Ph.D.
WEBSITE	agexinc.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	5

AgeX Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for AgeX Therapeutics Inc? What does AGE stand for in stocks?

AGE is the stock ticker symbol of AgeX Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AgeX Therapeutics Inc (AGE)?

As of Thu Nov 21 2024, market cap of AgeX Therapeutics Inc is 43.57 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AGE stock?

You can check AGE's fair value in chart for subscribers.

Is AgeX Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether AGE is over valued or under valued. Whether AgeX Therapeutics Inc is cheap or expensive depends on the assumptions which impact AgeX Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AGE.

What is AgeX Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Nov 21 2024, AGE's PE ratio (Price to Earnings) is 3.16 and Price to Sales (PS) ratio is 14.86. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AGE PE ratio will change depending on the future growth rate expectations of investors.